Aptamers for Targeted Drug Delivery
Open Access
- 26 May 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 3 (6), 1761-1778
- https://doi.org/10.3390/ph3061761
Abstract
Aptamers are a class of therapeutic oligonucleotides that form specific three-dimensional structures that are dictated by their sequences. They are typically generated by an iterative screening process of complex nucleic acid libraries employing a process termed Systemic Evolution of Ligands by Exponential Enrichment (SELEX). SELEX has traditionally been performed using purified proteins, and cell surface receptors may be challenging to purify in their properly folded and modified conformations. Therefore, relatively few aptamers have been generated that bind cell surface receptors. However, improvements in recombinant fusion protein technology have increased the availability of receptor extracellular domains as purified protein targets, and the development of cell-based selection techniques has allowed selection against surface proteins in their native configuration on the cell surface. With cell-based selection, a specific protein target is not always chosen, but selection is performed against a target cell type with the goal of letting the aptamer choose the target. Several studies have demonstrated that aptamers that bind cell surface receptors may have functions other than just blocking receptor-ligand interactions. All cell surface proteins cycle intracellularly to some extent, and many surface receptors are actively internalized in response to ligand binding. Therefore, aptamers that bind cell surface receptors have been exploited for the delivery of a variety of cargoes into cells. This review focuses on recent progress and current challenges in the field of aptamer-mediated delivery.Keywords
This publication has 82 references indexed in Scilit:
- In vivo selection of tumor-targeting RNA motifsNature Chemical Biology, 2009
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumorsNature Biotechnology, 2009
- Viral Capsid DNA Aptamer Conjugates as Multivalent Cell-Targeting VehiclesJournal of the American Chemical Society, 2009
- Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor CellsChemBioChem, 2009
- Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancerExperimental and Molecular Pathology, 2009
- Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 TherapyMolecular Therapy, 2008
- Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating AptamerCell Chemical Biology, 2008
- Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer CellsJournal of Proteome Research, 2008
- Aptamers evolved from live cells as effective molecular probes for cancer studyProceedings of the National Academy of Sciences of the United States of America, 2006
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences of the United States of America, 2006